Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jazz Pharmaceuticals
Biotech
Jazz pays Saniona $42.5M to add prospect to epilepsy ensemble
Jazz has landed global rights to a preclinical asset designed to address problems faced by GSK’s withdrawn drug Potiga.
Nick Paul Taylor
Aug 20, 2025 9:13am
Pfizer’s reputation wrangler plans departure—Chutes & Ladders
Jul 11, 2025 8:30am
Chimerix had 8 suitors: Why Jazz won out
Mar 21, 2025 5:17pm
Jazz hands Chimerix $935M to buy near-approval cancer drug
Mar 5, 2025 8:13am
FDA's principal deputy to depart agency—Chutes & Ladders
Dec 20, 2024 8:30am
ESMO: Jazz HER2 bispecific posts 59% survival at 30 months
Sep 16, 2024 3:00am
